Alibaba Health Information Technology Limited

Alibaba Health Information Technology Limited

ALBBY
Alibaba Health Information Technology LimitedUS flagOther OTC
9.35
USD
+0.95
- -
7.54BMarket Cap
Alibaba Health Information Technology Limited
ALBBY
(Other OTC)

Recent

price

9.35

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
FRC
1.69
2.1
0.07
0.12
0.08
0.14
1.16
5.32
9.22
16.09
23.43
30.52
39.64
38.49
38.08
42.53
Revenue per Share
-0.12
-0.03
-0.18
-0.17
-0.21
-0.47
-0.51
-0.23
-0.15
-0.01
0.53
-0.39
0.79
1.26
1.78
2.4
Basic EPS, GAAP
-0.18
-0.05
-0.08
-0.01
-0.15
-0.31
-0.56
-0.17
0.71
0.96
1.5
0.61
0.37
1.51
1.71
1.52
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.17
0.16
0.16
0.2
0.19
0.18
0.18
0.19
0.19
0.18
-1.31
-1.77
-1.07
0.19
1.83
4.09
Book Value per Share
1.6
1.56
1.07
1.36
3.24
2.83
2.69
5.45
4.9
8.62
21.48
19.18
20.78
19.1
18.95
20.85
Tangible Book Value per Share
186
186
186
186
391
409
409
459
553
597
662
674
675
702
804
806
Basic Weighted Avg Shares
314
391
13
22
30
57
475
2,443
5,096
9,596
15,518
20,578
26,763
27,027
30,598
34,255
Sales/Revenue/Turnover
-8.4
-6.97
-268.84
-164.1
-440.87
-372.37
-41.66
-5.29
-1.83
-0.44
0.71
-4.95
0.19
2.64
5.15
5.52
Operating Margin (%)
23
23
14
5
8
4
5
5
4
42
40
61
64
54
58
53
Depreciation Expense
-22
-6
-33
-31
-81
-192
-208
-107
-82
-7
349
-266
536
883
1,432
1,936
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
272.6
14.59
- -
2.63
5.99
8.2
14.86
Effective Tax Rate (%)
-7.08
-1.61
-260.21
-142.61
-273.07
-338.56
-43.7
-4.38
-1.61
-0.07
2.25
-1.29
2
3.27
4.68
5.65
Profit Margin (%)
116
61
39
109
1,112
850
457
1,436
70
2,403
10,799
8,743
9,476
8,487
7,534
10,329
Working Capital
- -
- -
- -
- -
- -
- -
200
- -
- -
38
17
85
40
48
25
30
LT Debt
340
324
230
282
1,267
1,155
1,120
2,523
2,737
5,203
14,282
14,070
15,147
14,518
16,313
17,857
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.5
0.97
- -
0.34
4.48
9.3
9.35
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
-3.82
-96.35
- -
-61.62
-366.85
169.84
79.77
Return on Capital (%)
- -
-20.41
-110.41
-94.02
-148.73
-265
-286.8
-134.48
-86.48
-6.3
309.9
- -
- -
- -
179.27
81.36
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
41.92%
4.77%
9.46%
Free Cash Flow
-23.39%
48.98%
-10.79%
Net Income, GAAP
-586.4%
-63.13%
35.17%
Sales/Revenue/Turnover
150.1%
17.76%
11.95%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
27,027
2025
- -
- -
- -
- -
30,598
2026
- -
- -
- -
- -
34,255

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.26
2025
- -
- -
- -
- -
1.78
2026
- -
- -
- -
- -
2.4

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Alibaba Health Information Technology Limited is an investment holding company primarily engaged in providing Internet technology solutions, service tools, and platforms for the medical and healthcare sectors. The company operates a comprehensive pharmaceutical e-commerce platform; pharmaceutical direct sales; consumer healthcare product sales; digital healthcare services including drug safety tracking and anti-counterfeiting solutions through its "Ma Shang Fang Xin" platform; as well as cloud computing and big data-enabled internet healthcare services. Alibaba Health acts as the healthcare flagship platform of Alibaba Group, focused on integrated online and offline medical and healthcare resource solutions within China. Founded in 1998 and headquartered in Hong Kong, the company serves a broad customer base including pharmaceutical companies, healthcare institutions, and consumers across China. Recent major developments include a strategic acquisition deal announced in late 2023, under which Alibaba Health acquired rights related to Alibaba’s digital marketing platform Alimama to enhance its advertising and promotional content validation capabilities for healthcare products, expected to drive revenue growth and improve service delivery to online retailers. In 2024, Alibaba Health reported robust growth with total revenue increasing to RMB 14.27 billion and net profit rising by 72.8% year-on-year, driven primarily by significant expansion in pharmaceutical e-commerce and direct sales businesses supported by a broader product offering and enhanced advertising capabilities. The company also continues to invest in its digital infrastructure and AI applications across business segments to optimize operational efficiency and expand its healthcare service offerings with an ambition to serve 500 million people within five years. Alibaba Health’s recent operational adjustments include business streamlining efforts in its healthcare and digital services sector to focus on high-growth and high-margin areas. The company’s business segments encompass internet healthcare technology solutions, pharmaceutical supply chain services, consumer healthcare e-commerce platforms, and innovative digital health management. Alibaba Health’s platform ecosystem integrates pharmaceutical product sales, medication safety tracking, and healthcare content services to meet the evolving needs of China’s healthcare market. Alibaba Health Information Technology Limited is a subsidiary of Alibaba Group, headquartered in Causeway Bay, Hong Kong. It was founded in 1998 and formally adopted its current name in 2014 following a reorganization from CITIC 21CN Company Limited. The company employs over 1,300 people and maintains a strategic focus on leveraging digital technologies, including AI and big data, to transform healthcare services in mainland China. Recent acquisitions and partnerships signify Alibaba Health’s intent to consolidate its market leadership in pharmaceutical e-commerce and digital healthcare innovation.